Phenom Named Strategic Leader in Fosway’s 9-Grid™ for Talent Acquisition 2023 for Third Consecutive Year
22.5.2023 12:00:00 EEST | Business Wire | Press release
Phenom has been named a Strategic Leader in the 2023 Fosway 9-GridTM for Talent Acquisition for the third consecutive year, proving its ability to deliver higher levels of innovation, customer impact and advocacy compared to alternatives in the market. Fosway identifies Strategic Leaders as companies that provide a rich suite of capability across a broad scope of features and have the sophistication to consistently meet the needs of complex enterprise-scale customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005161/en/
Strategic Leader position reaffirms Phenom and its Intelligent Talent Experience platform’s consistent ability to serve EMEA’s largest companies’ complex talent demands. (Graphic: Business Wire)
Job vacancy rates recently reached record highs and the competitive talent market remains a priority on the European Union’s policy agenda, according to a European Labour Authority report. To better connect with candidates and quickly fill open roles in a scalable, sustainable way, CHROs and CEOs from today’s leading enterprises are choosing holistic solutions that leverage intelligence, automation and experience to reduce repetitive tasks, increase recruiter efficiency and hyper-personalize every part of the talent journey.
“Artificial intelligence (AI) is accelerating disruption in the TA market,” said David Wilson, CEO, Fosway Group. “Phenom’s position as a Strategic Leader on the 2023 Fosway 9-Grid™ for Talent Acquisition reflects the company’s continued innovation in AI and the candidate and talent experience. Recent acquisitions continue to give the company even greater traction in the European market.”
More than 500 global, diverse enterprises use Phenom’s vast network of data, contextual industry models and deep learning to achieve measurable, defensible results. Case studies of customers using the Intelligent Talent Experience platform document their ability to:
- Generate 11X more internal and external applications and achieved a 50% reduction in time to apply
- Drive a 176% increase in applications and 165% increase in hires YOY
- Deliver 8X more candidates and 20% faster hires
- Save up to 78% of recruiters’ time with automated screening and scheduling
- Decrease time to schedule an interview 98% (from 5 minutes to 5 seconds) with automation
- Increase recruiter productivity 567% and reduce agency spend
- Cut 65 days off time to hire
“Phenom continues to deliver innovation, scale technology and elevate customer support to solve the most complex talent demands of the largest enterprises across Europe,” said Mahe Bayireddi, CEO and co-founder of Phenom. “We are fully invested in the success of our customers’ teams, their outcomes and the incredible impact they’re able to drive for talent acquisition and management — and the business as a whole.”
In addition to their existing talent acquisition technology — including Career Site, CMS, CRM, Video Assessments and AI Scheduling — Phenom recently announced Phenom X+, a new platform-wide generative AI capability that bolsters efficiencies by automating content creation, surfacing actionable intelligence, and eliminating time-consuming tasks. Phenom also unveiled 18 platform intelligence and automation innovations to further transform the way employers teams hire, develop and retain talent.
Platform innovation highlights include:
- Generative AI for TA — providing sourcers, recruiters, talent marketers, and other talent acquisition professionals the ability to generate personalized content that delights candidates and dramatically speeds up the hiring process by eliminating time-consuming, manual work.
- High-Volume Hiring — automating job discovery, application submission, and offering extension processes for frontline and hourly workers.
- Automation Engine — giving organizations the backend interface and control needed to configure and iterate on hiring workflows – complete with intelligence for ongoing monitoring and qualitative analysis of performance, plus recommendations to optimize in real-time.
- Interview Intelligence — eliminating the black box of the interview process by providing transcripts, key takeaways, and actionable guidance to the hiring team to move forward with decisions faster.
- Workforce Intelligence — providing context and oversight to HR teams within their organization, including hiring trends, churn rate, retention risks and high performers, to improve talent onboarding, development and retention.
- Candidate Hub – bringing transparency to candidates throughout the hiring process, making it easy to discover relevant roles, understand hiring status, prepare for interviews, and reschedule when conflicts arise.
Companies across EMEA are successfully adopting Phenom’s Intelligent Talent Experience platform to help candidates find and choose them faster, employees develop their skills and evolve, recruiters become wildly productive, managers build stronger-performing teams, HR align employee development with company goals and HRIS create a holistic tech infrastructure through seamless integrations.
To learn more about Phenom’s Strategic Leader position, read this blog.
To see the Phenom Intelligent Talent Experience platform in action, request a demo.
About the Fosway 9-Grid™
Fosway Group is Europe’s #1 HR industry analyst. The Fosway 9-Grid™ provides a unique assessment of the principal learning and talent supply options available to organizations in EMEA. The analysis is based on extensive independent research and insights from Fosway’s Corporate Research Network of over 250 organizations, including BP, HSBC, PwC, RBS, Sanofi, Shell, and Vodafone. Visit the Fosway website at www.fosway.com.
About Phenom
Phenom has a purpose of helping a billion people find the right job. Through AI-powered talent experiences, employers are using Phenom to hire employees faster, develop them to their full potential, and retain them longer. The Phenom Intelligent Talent Experience platform seamlessly connects candidates, employees, recruiters, hiring managers, HR and HRIS — empowering over 500 diverse and global enterprises with innovative products including Phenom Career Site, Chatbot, CMS, CRM, AI Scheduling, Video Assessments, Campaigns, University Recruiting, Talent Marketplace, Career Pathing, Gigs, Mentoring, and Referrals.
Phenom has earned accolades including: Inc. 5000’s fastest-growing companies (3 consecutive years), Deloitte Technology's Fast 500 (4 consecutive years), five Brandon Hall ‘Excellence in Technology’ awards including Gold for ‘Best Advance in AI for Business Impact,’ Business Intelligence Group's Artificial Intelligence Excellence Awards (3 consecutive years), and a regional Timmy Award for launching and optimizing HelpOneBillion.com (2020).
Headquartered in Greater Philadelphia, Phenom also has offices in India, Israel, the Netherlands, Germany and the United Kingdom.
For more information, please visit www.phenom.com. Connect with Phenom on LinkedIn, Twitter, Facebook, YouTube and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005161/en/
Contact information
Media:
Jennifer Lyons
Director, Global Communications
267-379-5066
jennifer.lyons@phenompeople.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
